CD80 and neoplasm: NCT04145622 is testing anti-B7-H3 ifinatamab deruxtecan (ADC DS-7300a), and NCT05914116 is investigating DB-1311, a humanized anti-B7-H3 mAb linked to a cleavable DNA topoisomerase I inhibitor for their anti-tumor activity [103].